Diabetes insipidus Medical Services in China

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, leading to excessive production of dilute urine (polyuria) and intense thirst (polydipsia). Unlike diabetes mellitus, DI is not related to blood glucose dysregulation but rather stems from defects in the antidiuretic hormone (ADH), also known as vasopressin, pathway. There are four primary subtypes: central (neurogenic) DI, caused by deficient ADH synthesis or secretion due to hypothalamic or pituitary damage; nephrogenic DI, resulting from renal resistance to ADH due to genetic mutations (e.g., AVPR2 or AQP2 genes) or acquired causes such as chronic lithium use, hypercalcemia, or hypokalemia; gestational DI, a transient form linked to placental vasopressinase overexpression during pregnancy; and primary polydipsia (dipsogenic DI), driven by abnormal thirst regulation and excessive water intake that suppresses ADH release. Pathophysiologically, impaired ADH signaling disrupts aquaporin-2 water channel trafficking in the renal collecting ducts, preventing water reabsorption and causing persistent urinary water loss—often exceeding 3–20 L per day. Epidemiologically, DI affects approximately 1 in 25,000 to 1 in 50,000 individuals globally, with central DI accounting for ~75% of cases. Incidence peaks in adults aged 30–50 years, though congenital forms present in infancy. Risk factors include traumatic brain injury, neurosurgery (especially transsphenoidal procedures), autoimmune hypophysitis, infiltrative diseases (e.g., sarcoidosis, histiocytosis), pituitary tumors (e.g., craniopharyngioma), and long-term lithium therapy. Genetic forms—particularly X-linked nephrogenic DI—predominate in pediatric populations. Untreated DI significantly impairs quality of life: patients experience sleep disruption from nocturia, fatigue, cognitive fog, anxiety around fluid access, and social withdrawal. Chronic dehydration risks include electrolyte imbalances (notably hypernatremia), acute kidney injury, and, in vulnerable populations (e.g., elderly or cognitively impaired), delirium or seizures. Early diagnosis requires careful differentiation from psychogenic polydipsia and diabetes mellitus via serum sodium, plasma osmolality, urine osmolality, and formal water deprivation testing with desmopressin challenge. Misdiagnosis is common and delays appropriate management, underscoring the need for specialized endocrinology evaluation.

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine due to deficient or ineffective antidiuretic hormone (ADH; also known as arginine vasopressin, AVP) signaling. This results in polyuria (excessive dilute urine output, often >3 L/day in adults), polydipsia (intense thirst), and risk of hypernatremia and dehydration if fluid intake is inadequate. DI is classified into four primary subtypes: central (neurogenic), nephrogenic, gestational, and primary polydipsia (dipsogenic)—though the latter is not a true form of DI and represents excessive water intake rather than a defect in AVP physiology.

Central diabetes insipidus arises from impaired synthesis, transport, or release of AVP from the hypothalamus or posterior pituitary. Common causes include structural brain injury—such as traumatic brain injury, neurosurgery (especially transsphenoidal resection of pituitary adenomas or craniopharyngiomas), or intracranial tumors (e.g., germinomas, metastases, lymphomas). Autoimmune hypophysitis, granulomatous diseases (e.g., sarcoidosis, tuberculosis, histiocytosis X), and infectious processes (e.g., meningitis, encephalitis) may infiltrate or inflame the hypothalamic–pituitary axis. Idiopathic cases account for ~25–50% of adult-onset central DI and may reflect undetected autoimmune or inflammatory mechanisms. Rarely, central DI occurs in association with Wolfram syndrome (DIDMOAD), a progressive neurodegenerative disorder involving mutations in the WFS1 gene.

Nephrogenic diabetes insipidus results from renal resistance to AVP, most commonly due to mutations in the AVPR2 gene (X-linked recessive, affecting the V2 receptor) or the AQP2 gene (autosomal recessive or dominant, encoding aquaporin-2 water channels). These genetic defects impair cAMP-mediated insertion of aquaporin-2 into the collecting duct apical membrane, preventing water reabsorption. Acquired nephrogenic DI is more prevalent and frequently triggered by chronic lithium therapy (a major iatrogenic cause), hypercalcemia, hypokalemia, obstructive uropathy, and chronic kidney disease (particularly interstitial nephritis). Certain medications—including demeclocycline, ofloxacin, and cisplatin—may also induce transient or persistent nephrogenic DI.

Gestational diabetes insipidus is a transient, acquired form occurring in late pregnancy due to excessive placental vasopressinase (an enzyme encoded by the ENPP2 gene), which degrades circulating AVP. Risk increases with multiple gestations, preeclampsia, and maternal liver disease (e.g., HELLP syndrome), which may upregulate vasopressinase expression. It typically resolves within 4–6 weeks postpartum.

Genetic factors play a pivotal role in familial forms. Autosomal dominant central DI is linked to mutations in the AVP gene (chromosome 20p13), causing misfolding and intracellular accumulation of mutant prepro-AVP, leading to progressive neuronal toxicity in magnocellular neurons—a phenomenon termed 'gain-of-toxic-function'. X-linked nephrogenic DI (AVPR2 mutations) predominantly affects males; female carriers may exhibit mild symptoms due to skewed X-inactivation. AQP2-related nephrogenic DI shows variable penetrance and may present neonatally with life-threatening hypernatremia or later in childhood.

Environmental and modifiable risk factors include prolonged lithium exposure (>1 year, cumulative dose >1000 g), recurrent urinary tract obstruction, chronic heavy metal exposure (e.g., cadmium), and uncontrolled hypercalcemia secondary to malignancy or primary hyperparathyroidism. Critically ill patients in intensive care settings are at heightened risk due to hemodynamic instability, sepsis-induced cytokine-mediated AVP dysregulation, and iatrogenic factors such as high-dose IV saline or diuretic use. Age is a non-modifiable risk factor: central DI peaks in the fifth to sixth decades (often post-surgical or tumor-related), while congenital nephrogenic DI presents in infancy with failure to thrive, fever, and irritability. Sex influences epidemiology—AVPR2 mutations confer male predominance in nephrogenic DI, whereas gestational DI exclusively affects females. Finally, socioeconomic and healthcare access factors indirectly influence outcomes: delayed diagnosis in resource-limited settings increases morbidity from recurrent dehydration and electrolyte emergencies.

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine due to deficient or ineffective antidiuretic hormone (ADH; also known as arginine vasopressin, AVP) signaling. It results in excessive production of dilute urine (polyuria) and compensatory excessive thirst (polydipsia). Unlike diabetes mellitus, DI does not involve hyperglycemia or insulin dysfunction; rather, it reflects a disturbance in water homeostasis mediated by the hypothalamic–pituitary–renal axis. DI is classified into four primary subtypes: central (neurogenic), nephrogenic, gestational, and primary polydipsia (psychogenic or dipsogenic), each with distinct pathophysiology but overlapping clinical manifestations.

Early symptoms of DI are often subtle and may be overlooked, particularly in adults with gradual onset. The earliest recognizable sign is persistent, unexplained polydipsia—typically exceeding 2.5 L/day and often reaching 5–20 L/day—without concomitant osmotic stimuli such as hyperglycemia or hypercalcemia. Patients frequently report waking at night to drink water (nocturnal polydipsia) and an urgent need to urinate immediately upon drinking. In infants and young children, early signs include irritability, poor feeding, failure to thrive, unexplained fevers, constipation, and recurrent dehydration episodes. Infants may present with hypotonia, lethargy, or hyperthermia secondary to undetected hypernatremia. Older children may exhibit enuresis, bed-wetting despite prior toilet training, or behavioral changes such as restlessness or difficulty concentrating at school.

Typical symptoms reflect the core pathophysiology: profound polyuria (>3 L/day in adults; >2 mL/kg/hour in children) and intense, unquenchable thirst. Urine output is consistently dilute, with specific gravity <1.005 and osmolality <200 mOsm/kg—often as low as 50–100 mOsm/kg—despite elevated serum osmolality (>295 mOsm/kg) and hypernatremia (serum sodium >145 mmol/L). Patients commonly describe pale, almost colorless urine with minimal odor. Polyuria persists regardless of fluid intake restriction, distinguishing DI from physiologic diuresis. In untreated or inadequately managed cases, symptoms worsen with intercurrent illness, fever, or reduced oral intake, precipitating acute decompensation.

Accompanying symptoms arise from chronic volume depletion and electrolyte imbalance. These include fatigue, headache, dry mucous membranes, orthostatic dizziness or lightheadedness, and decreased skin turgor. Cognitive effects such as confusion, impaired attention, and short-term memory deficits may occur with mild-to-moderate hypernatremia (145–155 mmol/L); severe hypernatremia (>155 mmol/L) can cause muscle twitching, lethargy, seizures, or coma. In children, growth retardation and delayed puberty may develop due to chronic catabolic stress and disrupted hypothalamic-pituitary-gonadal axis function. Nephrocalcinosis and urinary tract infections are more common in chronic nephrogenic DI due to persistently high urine volumes and low urinary calcium solubility.

Complications of untreated or mismanaged DI include recurrent episodes of hypernatremic dehydration, which increase risk for thromboembolic events, acute kidney injury, and rhabdomyolysis. Chronic hypernatremia contributes to vascular stiffness and endothelial dysfunction, potentially accelerating cardiovascular morbidity. In central DI, underlying structural lesions (e.g., craniopharyngioma, metastatic tumor, or traumatic brain injury) may cause additional neuroendocrine deficits—such as growth hormone deficiency, hypothyroidism, adrenal insufficiency, or hypogonadism—leading to fatigue, weight gain, cold intolerance, or amenorrhea. Nephrogenic DI carries long-term renal risks, including medullary cyst formation, interstitial fibrosis, and progressive chronic kidney disease, especially when associated with lithium therapy or genetic mutations in AVPR2 or AQP2 genes. Gestational DI typically resolves postpartum but may recur in subsequent pregnancies; it carries increased risk of maternal hypernatremia and fetal growth restriction if unrecognized.

Diagnosis relies on a stepwise approach integrating clinical assessment, biochemical testing, and dynamic challenge studies. Initial evaluation includes serum electrolytes (notably sodium, potassium, glucose, calcium, urea), plasma osmolality, and paired urine osmolality and specific gravity. A random urine osmolality <300 mOsm/kg in the setting of serum osmolality >295 mOsm/kg strongly suggests DI. The formal water deprivation test remains the gold standard for confirming DI and differentiating its subtypes: patients fast under close supervision while serial measurements of weight, vital signs, serum sodium, plasma osmolality, and urine osmolality are obtained until either a 3% weight loss occurs or serum sodium exceeds 150 mmol/L. In central DI, urine osmolality fails to rise above 300 mOsm/kg despite rising plasma osmolality; administration of exogenous desmopressin (1–2 µg intranasally or 2 µg IV) then elicits a >50% increase in urine osmolality. In nephrogenic DI, urine osmolality remains low (<300 mOsm/kg) both pre- and post-desmopressin. MRI of the brain with pituitary protocol is essential in suspected central DI to evaluate for hypothalamic–pituitary structural abnormalities, including absence of the posterior pituitary 'bright spot' on T1-weighted imaging. Genetic testing is indicated for familial or early-onset nephrogenic DI.

Differential diagnosis must exclude conditions mimicking polyuria–polydipsia syndrome. Diabetes mellitus must be ruled out via fasting glucose and HbA1c. Primary polydipsia (psychogenic or dipsogenic) shows preserved urine-concentrating ability during water deprivation and no response to desmopressin—but paradoxically, urine osmolality rises appropriately after spontaneous reduction in fluid intake. Hypercalcemia and hypokalemia impair renal concentrating ability and may induce nephrogenic-like DI; correction of these electrolyte disorders often reverses the phenotype. Chronic kidney disease, sickle cell nephropathy, and obstructive uropathy can cause polyuria but usually present with other renal markers (elevated creatinine, proteinuria, imaging abnormalities). Osmotic diuresis from mannitol, ethanol, or glucosuria must be excluded clinically and biochemically. Finally, certain medications—including lithium, demeclocycline, ifosfamide, and foscarnet—induce acquired nephrogenic DI and warrant thorough medication review. Accurate classification is critical, as treatment differs fundamentally: central DI responds to desmopressin replacement; nephrogenic DI requires thiazide diuretics, NSAIDs, and low-sodium diet; gestational DI is treated with desmopressin (resistant to placental vasopressinase); and primary polydipsia necessitates psychiatric evaluation and behavioral intervention—not desmopressin, which could precipitate hyponatremia.

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, resulting in polyuria (excessive urine output, often >3 L/day in adults), polydipsia (intense thirst), and risk of hypernatremia and dehydration. It arises from either deficient arginine vasopressin (AVP) secretion (central or neurogenic DI), renal resistance to AVP (nephrogenic DI), or less commonly, gestational or primary polydipsia. Accurate etiological differentiation—via water deprivation test, plasma/urine osmolality, serum sodium, and AVP measurement—is essential before initiating therapy. Management is tailored to the subtype and severity, with goals centered on maintaining euvolemia, normonatremia, and quality of life.

Conservative treatment forms the cornerstone of management, particularly in mild or transient cases and as adjunctive support across all subtypes. In central DI, patients are advised to maintain free access to water at all times; scheduled oral hydration (e.g., 15–20 mL/kg/day) helps prevent nocturnal dehydration and sleep disruption. Dietary sodium restriction (<2 g/day) reduces solute load and subsequent urine volume. Caffeine and alcohol intake must be minimized due to their diuretic effects. For nephrogenic DI, conservative strategies include high-fluid intake (often >4–5 L/day), low-sodium, low-protein diet (to reduce medullary solute gradient and glomerular filtration rate), and avoidance of NSAIDs if contraindicated. In infants and elderly patients, close monitoring of weight, skin turgor, capillary refill, and serum electrolytes is mandatory to detect early signs of volume depletion or hypernatremia. Behavioral counseling for primary polydipsia—including structured fluid intake schedules and cognitive-behavioral techniques—may reduce compulsive drinking.

Pharmacotherapy is indicated when conservative measures are insufficient. Desmopressin (DDAVP), a synthetic V2-receptor-selective AVP analog, is first-line for central DI. Available as intranasal spray, oral tablets, and sublingual melt, it has prolonged half-life (8–12 hours) and minimal pressor activity. Dosing is titrated to achieve urine output <2.5 L/day and serum sodium 135–145 mmol/L; typical adult doses range from 0.05–0.4 mcg twice daily. Overuse risks hyponatremia and water intoxication—thus, patients require education on dose adjustment during illness, fever, or reduced oral intake. For nephrogenic DI, thiazide diuretics (e.g., hydrochlorothiazide 12.5–25 mg/day) paradoxically reduce urine volume by inducing mild hypovolemia and enhancing proximal tubular reabsorption. Amiloride (5–10 mg/day) is frequently co-administered to prevent hypokalemia and counteract thiazide-induced upregulation of ENaC channels, which can worsen lithium-induced nephrogenic DI. In lithium-associated cases, reducing lithium dose or switching to alternatives (e.g., valproate) is prioritized. COX-2 inhibitors (e.g., celecoxib) may be considered off-label in refractory nephrogenic DI, though evidence remains limited. Intranasal or oral chlorpropamide (a sulfonylurea) is rarely used in partial central DI due to hypoglycemia risk and is not recommended in China per current NMPA guidelines.

Surgical intervention is reserved for specific etiologies of central DI. Transsphenoidal resection of pituitary adenomas, craniopharyngiomas, or Rathke’s cleft cysts may restore AVP synthesis if hypothalamic-pituitary axis integrity is preserved preoperatively. Similarly, decompression of hypothalamic compression from metastases or granulomatous lesions (e.g., sarcoidosis, histiocytosis) may improve AVP secretion. However, surgery carries inherent risks—including cerebrospinal fluid leak, meningitis, panhypopituitarism—and DI may persist or even worsen postoperatively. Therefore, surgical candidacy requires multidisciplinary evaluation by neuroendocrinology, neurosurgery, and neuroradiology teams. Radiotherapy is generally avoided in DI management due to delayed onset and potential for radiation-induced hypothalamic injury.

Treatment advantages in China reflect robust infrastructure, regulatory rigor, and integrated care models. The National Medical Products Administration (NMPA) has approved multiple high-bioavailability desmopressin formulations—including domestically manufactured sublingual melts and nasal sprays—with stringent batch consistency and stability testing. China’s tiered healthcare system enables seamless referral from community clinics to tertiary endocrine centers (e.g., Peking Union Medical College Hospital, Shanghai Jiao Tong University Affiliated Ruijin Hospital), where dynamic endocrine testing (e.g., hypertonic saline infusion test) and MRI pituitary protocols are standardized. Telemedicine platforms facilitate longitudinal monitoring of serum sodium and urine osmolality, especially in rural regions. Moreover, China’s national rare disease registry supports epidemiological research and accelerates clinical trial enrollment for novel therapies, including selective V2-receptor antagonists under investigation for nephrogenic DI. Cost-effectiveness is enhanced through inclusion of desmopressin and thiazides in the National Reimbursement Drug List, with out-of-pocket expenses reduced by >70% for insured patients.

Recovery and long-term management emphasize patient empowerment and prevention of complications. Patients should carry medical identification (e.g., wallet card stating 'Diabetes Insipidus – Requires Immediate Access to Water') and undergo annual endocrine review including pituitary hormone panel (ACTH, cortisol, TSH, IGF-1, gonadotropins), renal ultrasound, and bone mineral density assessment (particularly in chronic thiazide users). Education focuses on recognizing prodromal symptoms of hypernatremia (lethargy, confusion, muscle cramps) and hyponatremia (headache, nausea, seizures), with clear action plans for acute illness (e.g., temporary desmopressin hold during vomiting/diarrhea). Psychological support is integral: studies from Beijing Children’s Hospital report that >40% of pediatric DI patients experience anxiety related to nocturia and school-related fluid access limitations. Family members should be trained in emergency rehydration protocols and home sodium monitoring where available. Finally, women of childbearing age with central DI require preconception counseling, as pregnancy may alter desmopressin pharmacokinetics and increase risk of preeclampsia; close collaboration with maternal-fetal medicine specialists is advised. With comprehensive, individualized care, most patients achieve full functional recovery and normal life expectancy.